TargaGenix Inc. is a technology company.
TargaGenix Inc. has raised $100K across 1 funding round.
TargaGenix Inc. has raised $100K in total across 1 funding round.
TargaGenix Inc. is a biotechnology company developing novel cancer therapies, specifically a nanoemulsion formulation (DHA-SBT-1214) that targets both cancer stem cells and bulk tumor cells resistant to standard chemotherapy.[1][2][3] It serves healthcare providers, researchers, and oncology patients by addressing chemotherapy-resistant tumors, enhancing drug delivery via the Enhanced Permeability and Retention (EPR) effect, reducing side effects, and improving efficacy in preclinical models where it has cured animals with resistant tumor types.[1][2][7] Founded in 2013 in Stony Brook, NY, the company remains in the product development stage with seed funding of $840K raised about seven years ago, a small team of around three employees, and five patents in cancer treatments and oncology.[1][2]
TargaGenix was founded in June 2013 as a Stony Brook University spinout, licensing taxane compounds discovered through over a decade of research at the university.[1][2][7] The core product, DHA-SBT-1214, emerged from efforts to identify molecules effective against chemotherapy-resistant tumors, with further advancements in formulation, toxicity reduction, and in vivo efficacy post-licensing in 2016.[2][7] Key team member Dr. Egan brings extensive drug development experience, including raising over $90M at IRX Therapeutics and negotiating a company sale.[1] Early traction includes preclinical successes and new funding announced in March 2023 to accelerate the compound toward clinical trials.[2][7]
TargaGenix rides the wave of precision oncology and nanotechnology in drug delivery, targeting the critical challenge of cancer stem cells that drive recurrence and resistance—affecting over 50% of cases where standard therapies fail.[1][3] Timing aligns with surging investments in immuno-oncology and nano-therapeutics, bolstered by market forces like rising cancer incidence (projected 30% global increase by 2040) and demand for less toxic alternatives to traditional chemo.[2][7] As a university spinout, it contributes to the biotech ecosystem by translating academic research into viable therapies, influencing partnerships with institutions like Northeastern University and potentially accelerating next-gen taxanes for combination regimens.[2][7]
TargaGenix is poised for clinical trials following 2023 funding, focusing on standalone and combo therapies for resistant cancers, with nano-formulation refinements key to IND filing.[2][7] Trends like AI-driven drug discovery, personalized medicine, and nano-oncology tailwinds could propel it toward partnerships or acquisition by big pharma seeking stem cell-targeting assets. Its influence may grow by validating EPR-enhanced taxanes, bridging academia and clinic to reshape resistant tumor treatment—potentially delivering the breakthrough its preclinical data promises.[1][2][7]
TargaGenix Inc. has raised $100K in total across 1 funding round.
TargaGenix Inc.'s investors include Accelerate New York Seed Fund.
TargaGenix Inc. has raised $100K across 1 funding round. Most recently, it raised $100K Seed in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $100K Seed | Accelerate New York Seed Fund |